Pfizer Announces FDA Approves XELJANZ (tofacitinib) for the Treatment of Moderately to Severely…
Pfizer Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) 10 mg twice-daily (BID) for at least eight weeks, followed by…
Read More...
Read More...